<DOC>
	<DOC>NCT00529932</DOC>
	<brief_summary>An international, multi-centre, double-blind, randomised, placebo-controlled clinical trial with central core lab analyses to determine the safety of intra-coronary infusion of enriched CD133+, bone marrow-derived, autologous progenitor cells in patients 5-10 days after acute percutaneous coronary revascularization (primary PCI) for ST-segment elevation myocardial infarction (STEMI).</brief_summary>
	<brief_title>A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Primary PCI for acute STEMI between 224 hours after onset of chest pain. STsegment elevation &gt;=2mm in &gt;=3 adjacent leads. Presence of severe hypokinesia and/or akinesia in &gt;=2 adjacent segments on echocardiogram at 4872 hrs after primary PCI. Age between 20 and 75 years. Pregnant or lactating. Prior history of myocardial infarction before index event. Decompensated congestive heart failure. Preexistent LV dysfunction (EF &lt;45% prior to admission) Cardiomyopathy. Previous cardiac surgery. Congenital heart disorder. Serum creatinine &gt;200 Mmol/L. Presence of permanent pacemaker or implantable defibrillator. Contraindication to bone marrow aspiration. History of malignancy within 5 years except curatively treated basal cell carcinoma, squamous cell carcinoma and/or cervical carcinoma. Sustained or inducible VT &gt;48 hours post primary PCI. Three vessel coronary artery disease necessitating intervention within 4 months. Immune compromise including chronic human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. Presence of chronic systemic inflammatory disorders. Previous autologous or allogeneic bone marrow or peripheral stem cell transplant or prior solid organ transplantation. Low hemoglobin, white blood cell, absolute neutrophil and/or platelet count. Any condition associated with a life expectancy of less than 6 months. Participation in unrelated research involving investigational pharmacological agent(s) 30 days before planned dosing. Current alcohol or drug abuse. Inability to provide written informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Acute Myocardial Infarction</keyword>
	<keyword>Celltherapy</keyword>
	<keyword>Bone Marrow</keyword>
</DOC>